This bibliography is compiled by clinicians from the journals listed at the end of this publication. It is based on literature entered into our database between 1 November 2007 and 31 October 2008 (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.
• Papers considered by the reviewers to be of special interest
•• Papers considered by the reviewers to be of outstanding interest
The number in square brackets following a selected paper, e.g. , refers to its number in the annotated references of the corresponding review.
Differentiation therapy of acute myeloid leukemia: past, present and future
Review: (pp. 84–91)
Ahmed Z, Shaikh MA, Raval A, Mehta JB, et al. All-trans retinoic acid syndrome: Another cause of drug-induced respiratory failure. South Med J 2007; 100:899–902.
• Bug G, Schwarz K, Schoch C, et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007; 92:542–545.
Davidovici BB, Tuzun Y, Wolf R. Retinoid receptors. Dermatol Clin 2007; 25:525–.
De Santis GC, De Barros M, Sousa TRB, Moreno SE, et al. Adhesion. molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, AS(2)O(3), phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica 2007; 92:1615–1622.
Drumea K, Yang ZF, Rosmarin A. Retinoic acid signaling in myelopoiesis. Curr Opin Hematol 2008; 15:37–41.
•• Fazi F, Zardo G, Gelmetti V, et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 2007; 109:4432–4440.
•• Glasow A, Barrett A, Petrie K, et al. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood 2008; 111:2374–2377.
• Hattori H, Zhang X, Jia Y, et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007; 110:640–650.
Jacomo RH, Melo RAM, Souto FR, de Mattos ER, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007; 92:1431–1432.
• Jepsen K, Solum D, Zhou T, et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007; 450:415–419.
• Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741–750.
•• Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10:547–555.
McNamara S, Wang HL, Hanna N, Miller WH. Topoisomerase II beta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol 2008; 28:2066–2077.
• Meester-Smoor MA, Janssen MJ, Grosveld GC, et al. MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR induced gene expression. Carcinogenesis 2008; 29:2025–2034.
Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid-induced gene expression and myeloid differentiation. Mol Cancer Ther 2007; 6:3081–3090.
Miwako I, Kagechika H. Tamibarotene. Drugs Today 2007; 43:563–568.
Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment [Review]. Differentiation 2007; 75:853–870.
Okazuka K, Masuko M, Seki Y, Hama H, et al. Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion. Int J Hematol 2007; 86:246–249.
Qiu J, Huang Y, Chen G, Chen Z, et al. Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level. Mol Biol Cell 2007; 18:3941–3951.
Racanicchi L, Montanucci P, Basta GPP, Pensato A, et al. Effect of all trans retinoic acid on lysosomal alpha-D-mannosidase activity in Hl-60 cell: correlation with Hl-60 cells differentiation. Mol Cell Biochem 2008; 308:17–24.
Rajpurkar M, Alcasabas P, Warrier I, Valentini RP, et al. Effect of dialysis on all trans retinoic acid levels in a child with acute promyelocytic leukemia and renal failure. Pediatric Blood Cancer 2007; 49:994–996.
Si JT, Mueller L, Schuler A, Simon J, et al. The retinoic acid receptor/CaMKII interaction: Pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. Blood Cells Mol Dis 2007; 39.
Soriano AO, Yang H, Faderl S, Estrov Z, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302–2308.
• Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302–2308.
•• Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10:538–546.
Valappil S, Kurkar M, Howell R. Outcome of pregnancy in women treated with all-trans retinoic acid; A case report and review of literature. Hematology 2007; 12:415–418.
• van Wely KH, Meester-Smoor MA, Janssen MJ, et al. The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription. Oncogene 2007; 26:5733–5740.
• Wald DN, Vermaat HM, Zang S, et al. Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound. Cancer Res 2008; 68:4369–4376.
Wang T, Ma XC, Krausz KW, Idle JR, et al. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J Pharmacol Exp Ther 2008; 324:674–684.
•• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111:2505–2515.
Witcher M, Pettersson F, Dupere-Richer D, Padovani A, et al. Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. Nucleic Acids Res 2008; 36:435–443.
•• Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007; 92:323–331.
Molecular signatures in acute myeloid leukemia
Review: (pp. 64–69)
Adachi S, Manabe A, Imaizumi M, Taga T, et al. Acute myeloid leukemia with multifineage dysplasia in children. Int J Hematol 2007; 86:358–363.
Ahn JS, Yang DH, Kim YK, Cho SH, et al. Multiple intracranial tuberculomas mimicking granulocytic sarcomas in acute myeloid leukemia. J Korean Med Sci 2007; 22:S171–S173.
Bacher U, Haferlach C, Kern W, Haferlach T, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008; 111:2527–2537.
•• Baltimore D, Boldin MP, O'Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9:839–845.
Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007; 12:497–503.
Breccia M, Cimino G, Diverio D, Gentilini F, et al. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 2007; 92:1273–1274.
Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007; 21:2420–2427.
Buesche G, Teoman H, Wilczak W, Ganser A, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008; 22:313–322.
• Bullinger L, Döhner K, Kranz R, et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008; 111:4490–4495.
Buzzai M, Licht JD. New molecular concepts and targets in acute myeloid leukemia. Curr Opin Hematol 2008; 15:82–87.
Catalano A, Dawson MA, Somana K, Opat S, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007; 110:4073–4076.
Cortes J, Quintas-Cardama A, Garcia-Manero G, O'Brien S, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007; 110:2000–2006.
Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment [Review]. Curr Opin Oncol 2007; 19:635–649.
Garzon R, Garofalo M, Martelli MP, Briesewitz R, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105:3945–3950.
Gez S, Crossett B, Christopherson RI. Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. BBA-Proteins Proteomics 2007; 1774:1173–1183.
Hatfield KJ, Hovland R, Oyan AM, Kalland KH, et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008; 22:287–293.
Hellstrom-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008; 45:14–22.
Iwasaki T, Sugisaki C, Nagata K, Takagi K, et al. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia. Pathol Int 2007; 57:645–651.
Kaune KM, Baumgart M, Gesk S, Mitteldorf C, et al. Bullous Sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib - Interphase cytogenetic detection of BCR-ABL-positive lesional cells. Arch Dermatol 2008; 144:361–364.
Konieczna I, Horvath E, Wang H, Lindsey S, et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008; 118:853–867.
Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111:2329–2338.
Lu L, Zhang L, Xiao ZJ, Lu SH, et al. Neuropilin-1 in acute myeloid leukemia: Expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 2008; 49:331–338.
Lyubimova LS, Demidova IA, Ustinova EN, Gribanova EO, et al. Results of the second randomized trial of the treatment of acute promyelocytic leukemias, carried out by the Russian Research Group of hematology centers [Russian]. Gematol Transfuziol 2007; 52:3–9.
•• Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1919–1928.
Markowski TR, Martin DB, Kao GF, Lutz L, et al. Leukemia cutis: A presenting sign in acute promyelocytic leukemia. Arch Dermatol 2007; 143:1220–1221.
Matsunaga T, Fukai F, Miura S, Nakane Y, et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008; 22:353–360.
Meyer LH, Queudeville M, Eckhoff SM, Creutzig U, et al. Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood 2008; 111:2899–2903.
Mufti G. David Galton, myelodysplasia and little me!. Leuk Lymphoma 2007; 48:2286–2287.
Ngo N, Summary IAL, Naresh KN. Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia. Br J Haematol 2008; 140:279–286.
• O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205:585–594.
Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia - a review [Review]. Br J Haematol 2008; 140:123–132.
Park MH, Cho SA, Yoo KH, Yang MH, et al. Gene expression profile related to prognosis of acute myeloid leukemia. Oncol Rep 2007; 18:1395–1402.
Rajappa S, Varadpande L, Paul T, Jacob R, et al. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leuk Lymphoma 2008; 49:554–558.
Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia [Review]. Pediatr Clin North Am 2008; 55:21.
Runarsson G, Feltenmark S, Forsell PKA, Sjoberg J, et al. The expression of cytosolic phospholipase A(2) and biosynthesis of leukotriene B-4 in acute myeloid leukemia cells. Eur J Haematol 2007; 79:468–476.
•• Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909–1918.
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan WH, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia [Review]. Gene Chromosomes Cancer 2008; 47.
Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 2007; 118:304–309.
Travaglino E, Benatti C, Malcovati L, Della Porta MG, et al. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 2008; 80:216–226.
Uchiumi H, Matsushima T, Yamane A, Doki N, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol 2007; 86:137–142.
• Verhaak RGW, Wouters BJ, Erpelinck CAJ, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009; 94:131–134.
Wang HR, Gu CH, Zhu JY, Hua JYH, et al. PNAS-2: A novel gene probably participating in leukemogenesis. Oncology (Williston Park) 2006:423–429.
•• Wouters BJ, Löwenberg B, Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009; 113:291–298.
Advancements in the molecular pathogenesis of myelodysplastic syndrome
Review: (pp. 70–76)
Adeyinka A, Smoley S, Fink S, Sanchez J, et al. Isochromosome (X)(p10) in hematologic disorders: FISH study of 14 new cases show three types of centromere signal patterns. Cancer Genet Cytogenet 2007; 179:25–30.
Akoz AG, Engin H, Oztoprak N. Atypical presentation of retinoic acid syndrome that mimics septic arthritis in a patient with acute promyelocytic leukemia. Acta Oncol 2007; 46:1193–1194.
Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes [Review]. Cancer Invest 2008; 26:208–216.
Ban KC, Gao Y, Amin HM, Howard A, et al. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 2008; 111:2904–2908.
Barosi G, Mesa RA, Thiele J, Cervantes F, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008; 22:437–438.
Boveri E, Passamonti F, Rumi E, Pietra D, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008; 140:162–168.
Buccisano F, Maurillo L, Tamburini A, Del Poeta G, et al. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. Eur J Haematol 2008; 80:107–114.
Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13:377–383.
Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008; 22:646–649.
de The H, Zhu J, Lallemand-Breitenbach V, Guillemin MC, et al. Decrypting acute promyelocytic leukemia pathogenesis through therapy response [Spanish]. Med-Buenos Aires 2007; 67:70.
•• Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451:335–339.
Economopoulou C, Pappa V, Kontsioti F, Papageorgiou S, et al. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo Myelodysplastic Syndromes (MDS). Leuk Res 2008; 32:61–69.
Elliott MA, Verstovsek S, Dingli D, Schwager SM, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31:1503–1509.
Falini B. Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities? Leuk Lymphoma 2007; 48:2093–2095.
Follo MY, Finelli C, Bosi C, Martinelli G, et al. PI-PLC beta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008; 22:198–200.
Girrbach G. Case report - Use of iron chelate therapy for patients with myelodysplastic Syndromes (MDS) [German]. Onkologie 2007; 30:525.
Goh DH, Lee SH, Cho DC, Park SH, et al. Chronic idiopathic myelofibrosis presenting as cauda equina compression due to extramedullary hematopoiesis: A case report. J Korean Med Sci 2007; 22:1090–1093.
Haase D, Germing U, Schanz J, Pfeilstocker M, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110:4385–4395.
Han Q, Sun Z, Liu LH, Chen B, et al. Impairment in immuno-modulatory function of F1k1(+)CD31(-)CD(34) MSCs from MDS-RA patients. Leuk Res 2007; 31:1469–1478.
Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leuk Res 2007; 31:1389–1392.
Jurisic V, Terzic T, Pavlovic S, Colovic N, et al. Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. Pathol Res Pract 2008; 204.
Kaiafa G, Papadopoulos A, Ntaios G, Saouli Z, et al. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome. Ann Hematol 2008; 87:257–262.
Kannan-Thulasiraman P, Dolniak B, Kaur S, Sassano A, et al. Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids. Biochem Biophys Res Commun 2008; 368:983–989.
Knoll B, Rea DJ, Szoztek J, Nagorney DS, et al. Extramedullary hematopoiesis. Am J Hematol 2008; 83:171.
Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13:141–152.
Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92:1389–1398.
Li X, Wu LY, Ying SX, Chang CK, et al. Clonality investigation of morphologically dysplastic hematopoietic cells in myelodysplastic syndrome marrows. Int J Hematol 2008; 87:176–183.
Ma L, Ceuppens J, Kasran A, Delforge M, et al. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leuk Res 2007; 31:1373–1382.
Ma XM, Selvin S, Raza A, Foti K, et al. Clustering in the incidence of myelodysplastic syndromes. Leuk Res 2007; 31:1683–1686.
Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes [Review]. Leuk Lymphoma 2008; 49:427–438.
Malcovati L, Cazzola M. Myelodysplastic/myeloproliferative disorders. Haematologica 2008; 93:4–6.
McCarthy N. Myelodysplastic syndromes: Dia findings. Nat Rev Microbiol 2007; 7(10):726:726.
Meers S, Kasran A, Boon L, Lemmens J, et al. Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells. Leukemia 2007; 21:2411–2419.
Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol 2008; 15:121–126.
Mirza I, Frantz C, Clarke G, Voth AJ, et al. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 2007; 131:1719–1724.
Mohamedali A, Gaken J, Twine NA, Ingram W, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110:3365–3373.
Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol 2008; 45:60–70.
Nilsson L, Eden P, Olsson E, Mansson R, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q - myelodysplastic syndromes. Blood 2007; 110:3005–3014.
•• Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007; 67:11657–11667.
Ozbudak IH, Shilo K, Hale S, Aguilera NS, et al. Alveolar airspace and pulmonary artery involvement by extramedullary hematopoiesis - A unique manifestation of myelofibrosis. Arch Pathol Lab Med 2008; 132:99–103.
Palandri F, Iacobucci I, Martinelli G, Amabile M, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working party on CML. J Clin Oncol 2008; 26:106–111.
Papa V, Tazzari PL, Chiarini F, Cappellini A, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147–160.
Pfeilstocker M, Karlic H, Nosslinger T, Sperr W, et al. Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications [Review]. Leuk Lymphoma 2007; 48:1900–1909.
•• Rassool FV, Gaymes TJ, Omidvar N, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 2007; 67:8762–8771.
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45–52.
Rumi E, Passamonti F, Della Porta MG, Elena C, et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25:5630–5635.
Sadiq SA, Rammal M, Sara G. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. Multiple Sclerosis 2008; 14:272–273.
Saghafi M, Azarian A, Nohesara N. Primary hypertrophic osteoarthropathy with myelofibrosis. Rheumatol Int 2008; 28:597–600.
Samochatova EV, Moschan AA, Aleinikova OV, Bespalova AV, et al. Long-term results of combined treatment of acute promyelocytic leukemia in children and adolescents with gene therapy [Russian]. Ter Arkh 2007; 79:19–26.
Samochatova EV, Moschan AA, Aleinikova OV, Bespalova AV, et al. Long-term results of combined treatment of acute promyelocytic leukemia in children and adolescents with gene therapy [Russian]. Ter Arkh 2007; 79:26–30.
Sloand EM. Myelodysplastic syndromes: Introduction. Semin Hematol 2008; 45:1–2.
Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: Implications for therapy [Review]. Semin Hematol 2008; 45:39–48.
Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol 2007; 86:301–305.
Steensma DP, Porcher JC, Hanson CA, Lathrop CL, et al. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol 2007; 139:439–442.
Strom SS, Velez-Bravo V, Estey EH. Epidemiology of myelodysplastic syndromes. Semin Hematol 2008; 45:8–13.
Tartas NE, Foncuberta MC, Avalos JCS. Treatment of hematologic neoplasms during pregnancy [Spanish]. Med-Buenos Aires 2007; 67:729–736.
Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: a paradigm of effective collaboration among clinicians, pathologists, and scientists. Blood 2008; 111:1742.
Ueda T, Ito Y, Maeda M, Fukunaga Y. Massive periosteal reaction a presenting feature of acute megakaryocytic leukemia. Pediatr Int 2007; 49:1015–1017.
van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111:1067–1077.
Varga G, Kiss J, Varkonyi J, Vas V, et al. Inappropriate notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 2007; 13:311–319.
•• Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111:4297–4308.
Yoshida Y. Evolving new treatment for myelodysplastic syndromes. Int J Hematol 2007; 86:297–300.
Optimal sequencing of treatments for patients with myelodysplastic syndromes
Review: (pp. 77–83)
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008; 112:895–902.
•• Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586–4588.
Au WY, Tam S, Fong BM, Ho KL, et al. Prolonged oral arsenic trioxide therapy and neprholithiasis. Leuk Lymphoma 2007; 48:2233–2234.
• Bennett JM. MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83:858–861.
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638–1645.
•• Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. Blood (ASH Annual Meeting Abstracts), 2007 110: Abstract 817.
• Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007; 109:4158–4163.
Jabbour E, Kantarjian H, Cortes J, Thomas D, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders - Final result of a phase 2 study. Cancer 2007; 110:2012–2018.
•• Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26:3607–3613.
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52–57.
Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia [Review]. Leuk Lymphoma 2007; 48:2310–2322.
Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes [Review]. Curr Opin Oncol 2007; 19:656–659.
•• Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111:574–582.
• Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86–93.
Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American society of clinical oncology/American society of hematology clinical practice guideline update. J Clin Oncol 2008; 26:132–149.
Sekeres MA. New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clinical Lymphoma Myeloma 2007; 8:S7–S12.
Shimoda K, Shide K, Kamezaki K, Okamura T, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: Retrospective analysis of 39 patients in japan. Int J Hematol 2007; 85:338–343.
•• Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505–2511.
• Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246–4254.
• Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78:487–494.
• Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577–584.
Novel strategies for patients with chronic myeloproliferative disorders
Review: (pp. 129–134)
•• Bogani C, Ponziani V, Guglielmelli P, et al. Myeloproliferative Disorders Research Consortium. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008; 26:1920–1930.
•• Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26:2732–2736.
• Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33:67–73.
Deininger MWN, Cortes J, Paquette R, Park B, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007; 110:1509–1519.
Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health-Syst Pharm 2007; 64:S9–S15.
Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. J Manag Care Pharm 2007; 13:S8–S12.
Frame D. New strategies in in chronic controlling drug resistance myeloid leukemia. Am J Health-Syst Pharm 2007; 64:S16–S21.
Gianelli U, Vener C, Raviele PR, Savi F, et al. VEGF expression Correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. Am J Clin Pathol 2007; 128:966–973.
Jabbour E, Cortes JE, Ghanem H, O'Brien S, et al. Targeted therapy in chronic myeloid leukemia [Review]. Expert Rev Anticancer Ther 2008; 8:99–110.
•• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112:3065–3072.
Labussiere H, Hayette S, Tigaud I, Michallet M, et al. Treatment of chronic myeloid leukemia in 2007 [Review] [French]. Bull Cancer (Paris) 2007; 94:863–869.
• Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, postpolycythemia vera and postessential thrombocythemia. Leukemia 2007; 21:1964–1970.
• Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008; 22:1636–1638.
• Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23:180–182.
Nanda S, Moore H, Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 2007; 210:143–156.
Phan CL, Baharuddin PJNBM, Chin LP, Zakaria Z, et al. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet 2008; 180:60–64.
• Quintás-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22:965–970.
Roeder I, Glauche I. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses [Review]. J Mol Med 2008; 86:17–27.
Sessions J. Chronic myeloid leukemia in 2007. J Manag Care Pharm 2007; 13:S4–S7.
• Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21:1827–1828.
• Weinkove R, Reilly JT, McMullin MF, et al. Low-dose thalidomide in myelofibrosis. Haematologica 2008; 93:1100–1101.
• Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93:1412–1414.
Allogeneic hematopoietic cell transplantation for patients with myelofibrosis
Review: (pp. 140–146)
• Bacigalupo A, Dominietto A, Pozzi S, et al. Allogeneic hemopoietic stem transplant for patient with idiopathic myelofibrosis using a reduced intensity based conditioning regimen [abstract #684]. Blood 110(Part 1); 2007:210a.
•• Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110:4030–4036.
• Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31:1503–1509.
•• Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13:355–365.
• Kroeger N, Holler E, Kobbe G, et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [abstract #683]. Blood 110(Part 1); 2007:210a.
•• Kroger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109:1316–1321.
Kroger N, Thiele E, Zander A, Schwerdtfeger R, et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35:1719–1722.
•• Kroger N, Thiele J, Zander A, et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35:1719–1722.
•• Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007; 31:737–740.
• Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109:2083–2088.
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14–22.
• Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111:1862–1865.
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia
Review: (pp. 98–104)
Ades L, Sanz MA, Chevret S, Montesinos P, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111:1078–1084.
Armand P, Kim HT, Cutler CS, Ho VT, et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:28–35.
• Büchner T, Berdel WE, Kienast J, et al. Cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 359:651–653.
• Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters: an analysis of 3082 patients. Blood 2008; 111:2527–2537.
Baz R, Rodriguez C, Fu AZ, Jawde RA, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer 2007; 110:1752–1759.
• Bornhäuser M, Illmer T, Schaich M, et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007; 109:2264–2265.
• Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791–4797.
• Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110:979–985.
• Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc_ AML): biological and clinical features. Blood 2007; 109:874–885.
• Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008; 35:346–355.
• Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776–2784.
• Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat Methods Med Res 2007; 16:199–218.
• Liso A, Castiglione F, Cappuccio A, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica 2008; 93:1219–1226.
Maftoun-Banankhah S, Maleki A, Karandikar NJ, Arbini AA, et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol 2008; 129:300–308.
• Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26:5078–5087.
• Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110:1262–1270.
• Neubauer A, Maharry K, Mrózek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26:4603–4609.
• Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008; 26:4595–4602.
Poor results with intensified maintenance chemotherapy in acute promyelocytic leukemia. Nat Clin Pract Oncol 2007; 4:617–618.
• Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: results from AMLSG Trial AML HD98B. Haematologica 2009; 94:54–60.
•• Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909–1918.
•• Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26:5429–5435.
• Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with gemtuzumab ozogamicin monotherapy. Blood 2007; 109:4168–4170.
• Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007; 109:5164–5167.
• Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplication. Blood 2008; 111:1552–1559.
Wierzbowska A, Robak T, Krawczynska A, Pluta A, et al. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 2008; 87:97–106.
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, et al. Potential cure of acute myeloid leukemia - Analysis of 1069 consecutive patients in first complete remission. Cancer 2007; 110:2756–2760.
Novel postremission strategies in adults with acute myeloid leukemia
Review: (pp. 105–111)
Amadori S, Stasi R. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia. Curr Opin Hematol 2008; 15:95–100.
Burnett AK, Kell J. Tipifarnib in acute myeloid leukemia. Drugs Today 2007; 43:795–800.
Colado E, Alvarez-Fernandez S, Maiso P, Martin-Sanchez J, et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34(+) immature phenotype. Haematologica 2008; 93:57–66.
Eom KS, Kim HJ, Min WS, Lee S, et al. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. Eur J Haematol 2007; 79:398–404.
• Grovdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azacytidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy [abstract no. 818]. ASH Annual Meeting Abstracts 2007: 110.
•• Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110:4427–4435.
Jurcic JG. Ab therapy of AML: native anti-CD33 Ab and drug conjugates [Review]. Cytotherapy 2008; 10:7–12.
• Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008; 14:3077–3082.
Lofgren C, Lehmann S, Jonsson-Videsater K, Mollgard L, et al. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia. Ther Drug Monit 2007; 29:626–631.
Mato AR, Morgans A, Luger SM. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2008; 15:108–114.
Miyawaki S, Kawai Y, Takeshita A, Komatsu N, et al. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: Study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 2007; 86:343–347.
•• Qazilbash MH, Wieder ED, Thall PF, et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia [abstract no. 283]. ASH Annual Meeting Abstracts 2007: 110.
Raponi M, Lancet JE, Fan HT, Dossey L, et al. A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111:2589–2596.
Sugita J, Tanaka J, Kurosawa M, Fukuhara T, et al. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group. Eur J Haematol 2008; 80:160–163.
White D, Saunders V, Grigg A, Arthur C, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25:4445–4451.
Yamamoto K, Emi N, Kajiguchi T, Yamamori S, et al. Eosinophils derived from acute promyelocytic leukemia cells after arsenic trioxide treatment. Int J Hematol 2007; 85:456–457.
•• Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2008. http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2008-05-158311v1. [Epub ahead of print]
Zhang WG, Wang FX, Chen YX, Cao XM, et al. Combination chemotherapy homoharringtonine, and granulocyte in patients with with low-dose cytarabine, colony-stimulating factor priming relapsed or refractory acute myeloid leukemia. Am J Hematol 2008; 83:185–188.
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009
Review: (pp. 135–139)
Bao F, Polk P, Nordberg ML, Veillon DM, et al. Comparative gene expression analysis of a chronic myelogenous leukemia c-ell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res 2007; 31:1511–1520.
Busuttil DP. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival. Int J Lab Hematol 2008; 30:68–70.
• De Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141:745–747.
Deenik W, van der Holt B, Verhoef GEG, Smit WM, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111:2581–2588.
Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110:2828–2837.
Hochhaus A, Druker B, Sawyers C, Guilhot F, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111:1039–1043.
• Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008; 112:3965–3973.
Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia - How to use imatinib and what role for newer drugs? [Review]. Oncology (Williston Park) 2007:653–662.
Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110:2991–2995.
Jin LH, Tabe Y, Konoplev S, Xu YY, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7:48–58.
• Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007; 109:5143–5150.
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540–3546.
Kim AS, Goldstein SC, Luger S, Van Deerlin VM, et al. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia - A nonrandom event associated with imatinib? Am J Clin Pathol 2008; 129:639–648.
Kim PS, Lee PP, Levy D. Modeling imatinib-treated chronic myelogenous leukemia: Reducing the complexity of agent-based models. Bull Math Biol 2008; 70:728–744.
le Coutre P, Ottmann OG, Giles F, Kim DW, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834–1839.
•• Marin D, Milojkovic D, Olavarria E, et al. European Leukemia Net criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112:4437–4444.
Marshall HM, Hammond JM. Treatment options in imatinib-resistant chronic myelogenous leukemia. Ann Pharmacother 2008; 42:259–264.
Matsuo E, Miyazaki Y, Tsutsumia C, Inoue Y, et al. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: A study in Nagasaki prefecture, Japan. Int J Hematol 2007; 85:132–139.
Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008; 111:2200–2210.
Maziarz RT. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr Opin Hematol 2008; 15:127–133.
Nakayama S, Nagamura-Inoue T, Yokoyama K, Ohno N, et al. Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Int J Hematol 2007; 86:208–211.
Pawarode A, Sait SNJ, Nganga A, Coignet LJ, et al. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leuk Res 2007; 31:1589–1592.
Piccaluga PP, Malagola M, Rondoni M, Arpinati M, et al. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study. Haematologica 2007; 92:1721–1722.
Quintas-Cardama A, Cortes J. Nilotinib therapy in chronic myelogenous leukemia [Spanish]. Drugs Today 2007; 43:691–702.
Ramamoorthy SK, Pandita R, Prakash A, Ramaswamy NV, et al. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. Acta Haematol 2007; 118:141–145.
Sahay T, Schiffer CA. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. Curr Opin Hematol 2008; 15:134–139.
• Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204–3212.
Stromskaya TP, Rybalkina EY, Kruglov SS, Zabotina TN, et al. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochem-Moscow 2008:29–37.
Yu ZA, Lomaia EG, Vinogradova OY, Druzhkoea GA, et al. Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: Data from a multicenter non-randomized trial in Russia [Russian]. Ter Arkh 2007; 79:17–22.
Umbilical cord blood transplantation for acute myeloid leukemia
Review: (pp. 124–128)
• Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation: higher response rates in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood and Marrow Transplant 2007; 13:1145–1152.
•• Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. Blood 2007; 110:4543–4551.
• Liao C, Wu JY, Xu ZP, et al. Indiscernible benefit of high-resolution HLA typing in improving long-term clinical outcome of unrelated umbilical cord blood transplant. Bone Marrow Transplant 2007; 40:201–208.
• Lu X, Kondo Y, Takmatsu H, et al. CD16+CD56− NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 2008; 81:18–25.
Maeda T, Shiozawa E, Mayumi H, Usui T, et al. Histopathology of bone marrow reconstitution after umbilical cord blood transplantation for hematological diseases. Pathol Int 2008; 58:126–132.
•• Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008; 14:282–289.
•• Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109:1322–1330.
•• Terakura S, Azuma E, Murata M, et al. Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol of Blood and Marrow Transplant 2007; 13:822–830.
Tse WW, Zang SL, Bunting KD, Laughlin MJ. Umbilical cord blood transplantation in adult myeloid leukemia [Review]. Bone Marrow Transplant 2008; 41:465–472.
Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia [Review]. Curr Opin Oncol 2007; 19:660–666.
Vaccination as a therapeutic strategy in acute myeloid leukemia
Schmitt M, Schmitt A, Rojewski MT, Chen JF, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111:1357–1365.
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Review: (pp. 92–97)
•• Bullinger L, Rücker FG, Kurz S, et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110:1291–1300.
•• Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109:3658–3666.
• Gorin N-C, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:3183–3188.
•• Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111:5078–5085.
• Narimatsu H, Iino M, Ichihashi T, et al. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. Int J Hematol 2008; 88:154–158. doi: 10.1007/s12185-008-0108-1.
•• Paschka P, Radmacher MD, Marcucci G, et al. Gene expression profiling improves outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 2007; 25:359a.
Shide K, Shimoda HK, Kumano T, Karube K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22:87–95.
• Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia 2007; 21:1177–1182.
Second hematopoietic stem cell transplantation in myeloid malignancies
Review: (pp. 112–123)
• Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008; 9:831–839.
• Heinzelmann F, Lang PJ, Ottinger H, et al. Immunosuppressive total lymphoid radiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys 2008; 70:523–528.
•• Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008; 42:297–310.
Mielcarek M, Storer BE, Flowers MED, Storb R, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:1160–1168.
• Reich-Zeliger S, Bachar-Lustig E, Bar-Ilan A, Reisner Y. Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host antidonor memory effector cells. J Immunol 2007; 179:6389–6394.
• Tse WW, Zang SL, Bunting KD, Laughlin MJ. Umbilical cord blood transplantation in adult myeloid leukemia. Bone Marrow Transplant 2008; 41:465–472.
Novel mutants leading to myeloid disease
Chaligne R, James C, Tonetti C, Besancenot R, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110:3735–3743.
Cortes J, Jabbour E, Kantarjian H, Yin CC, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110:4005–4011.
Falini B, Mecucci C, Saglio G, Lo Coco F, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008; 93:439–442.
Gale RE, Green C, Allen C, Mead AJ, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776–2784.
Kawamura M, Kaku H, Taketani T, Taki T, et al. Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis. Cancer Genet Cytogenet 2008; 180:74–78.
Majumdar S, Mondal BC, Ghosh M, Dey S, et al. Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia. Eur J Cancer Prev 2008; 17:125–132.
Mead AJ, Linch DC, Hills RK, Wheatley K, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110:1262–1270.
O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242–2249.
Palmisano M, Grafone T, Ottaviani E, Testoni N, et al. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 2007; 92:1268–1269.
Pappa V, Papageorgiou S, Kontsioti F, Papageorgiou E, et al. Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia. Leuk Lymphoma 2007; 48:2437–2440.
Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia [Review]. Leukemia 2008; 22:240–248.
Scholl S, Melle C, Bleul A, Spies-Weisshart B, et al. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations. Leuk Lymphoma 2007; 48:2418–2423.
Shih LY, Liang DC, Huang CF, Chang YT, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008; 22:303–307.
Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma 2007; 48:2141–2144.
Su YC, Chen CB, Chang YT, Tung YT, et al. hSNF5/INI1 mutation analysis in acute myeloid leukemia. Int J Hematol 2008; 87:172–175.
Suzuki R, Onizuka M, Kojima M, Shimada M, et al. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol 2007; 86:422–428.
Yan LZ, Chen SN, Liang JY, Feng YF, et al. Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia. Int J Hematol 2007; 86:143–146.
Zhang WG, Konopleva M, Shi YX, McQueen T, et al. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100:184–198.
Recent advances in therapeutics
Andrieux J, Roche-Lestienne C, Geffroy S, Desterke C, et al. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genet Cytogenet 2007; 178:11–16.
Arsenic compound improves survival in acute promyelocytic leukemia patients. Oncology (Williston Park) 2007:1254.
Au WY, Tam S, Kwong YL. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk Res 2008; 32:357–358.
Bartolini G, Orlandi M, Papi A, Ammar K, et al. Growth inhibition and proapoptotic activity induction by IIF and valproic acid on RA-resistant leukemia cells. Anticancer Res 2008; 28:283–288.
Bornhauser BC, Bonapace L, Lindhol M D, Martinez R, et al. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 2007; 110:2084–2091.
Copland M, Pellicano F, Richmond L, Allan EK, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111:2843–2853.
Czuczman MS, Emmanouilides C, Darif M, Witzig TE, et al. Treatment-related Myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25:4285–4292.
Damaj G, Bernit E, Ghez D, Claisse JF, et al. Thalidomide in advanced mastocytosis. Br J Haematol 2008; 141:249–253.
Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 2008; 15:101–107.
Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2008; 49:543–553.
Fuhler GM, Drayer AL, Olthof SGM, Schuringa JJ, et al. Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell-derived factor-1-induced migration of CD34(+) cells from patients with myelodysplasia. Blood 2008; 111:359–368.
Gil L, Styczynski J, Dytfeld D, Debski R, et al. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res 2007; 27:4021–4025.
Gleissner B, Schlenk R, Bornhauser M, Berdel WE. Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia - Ongoing trials [Review]. Onkologie 2007; 30:657–NIL_1.
Huang XF, Luo SK, Xu J, Li J, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008; 111:2854–2865.
Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clinical Lymphoma Myeloma 2007; 8:S24–S34.
Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, et al. The prophylactic effect of Itraconazole capsules and Fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: A Japanese multicenter randomized, controlled study. Int J Hematol 2007; 85:121–127.
King ME, Rowe JM. Recent developments in acute myelogenous leukemia therapy. Oncologist 2007; 12:14–21.
Knipp S, Gattermann N, Schapira M, Kaferstein H, et al. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 2007; 31:1585–1587.
Koseki M, Asada N, Uryu H, Takeuchi M, et al. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol 2007; 86:403–406.
Liao YF, Hung HC, Hour TC, Hsu PC, et al. Curcumin induces apoptosis through an ornithine decarboxylase-dependent pathway in human promyelocytic leukemia HL-60 cells. Life Sci 2008; 82:367–375.
Meyer PN, Roychowdhury S, Kini AR, Alkan S. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells. Leuk Res 2008; 32:143–149.
Mi YC, Xue YP, Yu WJ, Liu SH, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma 2008; 49:524–530.
Park JA, Yun JH, Kang HI, Shin HY, et al. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Pediatric Blood Cancer 2008; 50:872–874.
Petersdorf SH, Rankin C, Head DR, Terebelo HR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Am J Hematol 2007; 82:1056–1062.
Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia [Review]. Cancer 2007; 110:1900–1910.
Rickles FR, Falanga A, Montesinos P, Sanz MA, et al. Bleeding and thrombosis in acute leukemia: What does the future of therapy look like? Thromb Res 2007; 120:S99–S106.
Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology American Society of Clinical Oncology clinical practice guideline update [Review]. Blood 2008; 111:25–41.
Royer PJ, Bougras G, Ebstein F, Leveque L, et al. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: Application to active immunotherapy. Exp Hematol 2008; 36:329–339.
Saraiya B, Gounder M, Dutta J, Saleem A, et al. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drug 2008; 19:411–420.
Seo T, Urasaki Y, Ueda T. Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int J Hematol 2007; 85:26–31.
Shachaf CM, Perez OD, Youssef S, Fan AC, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 2007; 110:2674–2684.
Steinberg M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [Review]. Clin Ther 2007; 29:2289–2308.
Suzuki K, Ohishi K, Sekine T, Masuya M, et al. Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to Myelodysplastic syndrome treated with methylprednisolone. Int J Hematol 2007; 85:344–349.
Thery JC, Jardin F, Massy N, Massy J, et al. Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment. Leuk Lymphoma 2008; 49:168–170.
Usuki K, Urabe A, Ikeda Y, Ohashi Y, et al. A Multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol 2007; 85:59–69.
Vasconcelos FC, Gattass CR, Rumjanek VM, Maia RC. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs 2007; 25:525–533.
Wang GP, Qi ZH, Chen FP. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer. Med Hypotheses 2008; 70:122–127.
Wei L, Zhu YS, Guo M, Yu Y, et al. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res 2007; 31:1565–1574.
Weidenaar AC, de Jonge HJM, Fidler V, ter Elst A, et al. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anticancer Drug 2008; 19:45–54.
Yeh TC, Liu HC, Wang LY, Chen SH, et al. The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J Pediatr Hematol Oncol 2007; 29:826–831.
Chromosomal aberrations in myeloid disease
Abdulhaq H, Rossetti JM. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs 2007; 16:1967–1975.
Al-Achkar W, Wafa A, Nweder MS. A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia. J Exp Clin Cancer Res 2007; 26:411–415.
Alfaro R, Perez-Granero A, Duran MA, Besalduch J, et al. Dup(1)(q21q32) as a sole cytogenetic event is associated to a leukemic transformation in Myelodysplastic Syndromes. Leuk Res 2008; 32:159–161.
Barlogie B, Tricot G, Haessler J, van Rhee F, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood 2008; 111:94–100.
Bishton M, Kenealy M, Johnstone R, Rasheed W, et al. Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents [Review]. Expert Rev Anticancer Ther 2007; 7:1439–1449.
Bussaglia E, Guardia R, Nomdedeu JF. A large exon 6 break in V-form acute promyelocytic leukemia: relevance to clinical management. Leukemia 2007; 21:2356–2357.
Chen CC, Gau JP, Yu YB, Lu CH, et al. Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). Adv Ther 2007; 24:907–920.
De Roos AJ, Deeg HJ, Davis S. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 2007; 18:1199–1208.
Dicker F, Haferlach C, Kern W, Haferlach T, et al. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110:1308–1316.
Eun B, Lee Y, Hong S, Kim J, et al. Hes6 controls cell proliferation via interaction with cAMP-response element-binding protein-binding protein in the promyelocytic leukemia nuclear body. J Biol Chem 2008; 283:5939–5949.
Evers C, Beier M, Poelitz A, Hildebrandt B, et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Gene Chromosomes Cancer 2007; 46.
Gondek LP, Haddad AS, O'Keefe CL, Tiu R, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007; 35:1728–1738.
Guidez F, Parks S, Wong HN, Jovanovic JV, et al. RAR alpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci USA 2007; 104:18694–18699.
Helias C, Struski S, Gervais C, Leymarie V, et al. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet 2008; 180:51–55.
Horikoshi A, Takei K, Hosokawa Y, Sawada S. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int J Hematol 2008; 87:118–125.
Ishikawa M, Yagasaki F, Okamura D, Maeda T, et al. A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia. Int J Hematol 2007; 86:238–245.
Ismail S, Ababneh N, Awidi A. Identification of atypical PML-RARA breakpoint in a patient with acute promyelocytic leukemia. Acta Haematol 2007; 118:183–187.
Kaune KM, Baumgart M, Gesk S, Mitteldorf C, et al. Bullous Sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib - Interphase cytogenetic detection of BCR-ABL-positive lesional cells. Arch Dermatol 2008; 144:361–364.
Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q [Review]. Br J Haematol 2008; 140:267–278.
Kreil S, Pfirrmann M, Haferlach C, Waghorn K, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007; 110:1283–1290.
Lee J, Lu X, Shin ES, Kern WF, et al. A novel subtelomeric translocation t(5;9) and a deletion of the RB1 gene in a patient with acute myeloid leukemia (AML-M0). Cancer Genet Cytogenet 2008; 181:36–39.
Li SG. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia [Review]. Leuk Lymphoma 2008; 49:19–26.
Maserati E, Pressato B, Valli R, Patitucci F, et al. Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. Cancer Genet Cytogenet 2007; 179:79–81.
Oren H, Yilmaz S, Sercan Z, Demircioglu F, et al. Isolated myelosarcoma development in an adolescent chronic myeloid leukemia patient with t(9;22)(q34;q11.2),+8,+14,+21, and der(1)(p36). Cancer Genet Cytogenet 2008; 182:43–45.
Pidala J, Pinilla-Ibarz J, Cualing HD. A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). Cancer Genet Cytogenet 2008; 182:46–49.
Sevilla J, Fernandez-Plaza S, Lassaletta A, Gonzalez-Vicent M, et al. Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1). J Pediatr Hematol Oncol 2007; 29:839–840.
Snijder S, Mellink CHM, van der Lelie H. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. Cancer Genet Cytogenet 2008; 180:149–152.
Stavropoulou C, Georgakakos VN, Manola KN, Pagoni M, et al. 5 ' RARA submicroscopic deletion from new variant translocation involving chromosomes 15, 17, and 18, in a case of acute promyelocytic leukemia. Cancer Genet Cytogenet 2008; 182:50–55.
Stubbs MC, Kim YM, Krivtsov AV, Wright RD, et al. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 2008; 22:66–77.
Tan D, Lau LC, Teng LM, Sane S, et al. Loss of the extra chromosome 21 in a patient with Down syndrome and myelodysplasia. Cancer Genet Cytogenet 2008; 180:79–82.
Tokita K, Maki K, Tadokoro J, Nakamura Y, et al. Chronic idiopathic myelofibrosis expressing a novel type of TEL- PDGFRB chimaera responded to imatinib mesylate therapy (vol 21, pg 190, 2007). Leukemia 2008; 22:672.
Udayakumar AM, Alkindi S, Pathare AV, Raeburn JA. Complex t(8;13;21)(q22;q14;q22) - A novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2). Arch Med Res 2008; 39:252–256.
Van den Akker J, Coppo P, Portnoi MF, Barbu V, et al. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia. Leuk Lymphoma 2007; 48:1858–1865.
Wilkins BS, Erber WN, Bareford D, Buck G, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111:60–70.
Woods-Swafford W, Vnencak-Jones CL, Loken MR, Manes B, et al. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission. Pediatric Blood Cancer 2008; 50:639–641.
Transcriptional regulation in leukaemia
Duechler M, Stanczyk M, Czyz M, Stepnik M. Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. Cancer Chemother Pharmacol 2008; 61:727–737.
Gangat N, Strand J, Lasho TL, Finke CM, et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008; 80:197–200.
Glasow A, Barrett A, Petrie K, Gupta R, et al. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood 2008; 111:2374–2377.
Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of quiescent and proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007; 25:3111–3120.
Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of Myelodysplastic syndromes. Semin Hematol 2008; 45:23–30.
Gupta M, Milani L, Hermansson M, Simonsson B, et al. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. Biochem Biophys Res Commun 2008; 366:848–851.
Hoemme C, Peerzada A, Behre G, Wang YP, et al. Chromatin modifications induced by PML-RAR alpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008; 111:2887–2895.
Huang Y, Qui J, Chen GQ, Dong S. Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RAR alpha, resulting in sequestration and decreased mobility of SMRT. Biochem Biophys Res Commun 2008; 365:258–265.
Keeshan K, Shestova O, Ussin L, Pear WS. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. Blood Cells Mol Dis 2008; 40.
Kim TK, Lee JS, Oh SY, Jin X, et al. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res 2007; 67:11133–11140.
Langabeer SE, Ainle FN, Conneally E, Lawler M. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 2007; 176:105–109.
Larsen TS, Hasselbalch HC, Pallisgaard N, Moller MB. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. APMIS 2007; 115:1267–1273.
Maratheftis CI, Bolaraki PE, Voulgarelis M. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. Am J Hematol 2007; 82:887–892.
Naifeld V, Cozza A, Berkofsy-Fessler W, Prehal J, et al. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V > F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007; 35:1668–1676.
Ng APP, Nin DS, Fong JH, Venkataraman D, et al. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. Mol Cancer Ther 2007; 6:2240–2248.
Pietra D, Li S, Brisci A, Passarnonti F, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111:1686–1689.
Shiraishi A, Joko T, Higashiyama S, Ohashi Y. Role of promyelocytic leukemia zinc finger protein in proliferation of cultured human corneal endothelial cells. Cornea 2007; 26:S55–S58.
Tagata Y, Yoshida H, Nguyen LA, Kato H, et al. Phosphorylation of PML is essential for activation of C/EBP epsilon and PU.1 to accelerate granulocytic differentiation. Leukemia 2008; 22:273–280.
Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007; 13:366–371.
Mutations in JAK2
Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110:4030–4036.
Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8:864–866.
Breccia M, Cannella L, Diverio D, Streponi P, et al. Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leuk Res 2008; 32:177–180.
Briere J. Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome [French]. Bull Acad Natl Med 2007; 191:535–548.
Frantz C, Sekora DM, Henley DC, Huang CK, et al. Comparative evaluation of three JAK2(V617F) mutation detection methods. Am J Clin Pathol 2007; 128:865–874.
Kantarjian HM, Giles F, Gattermann N, Bhalla K, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540–3546.
Koksal V, Etlik O, Arican-Baris ST, Baris I. A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation. Genetic Testing 2007; 11:463–466.
Kratz CP, Niemeyer CM, Karow A, Volz-Fleckenstein M, et al. Congenital transfusion-dependent anemia and thrombocytopenia with myelodysplasia due to a recurrent GATA1(G208R) germline mutation. Leukemia 2008; 22:432–434.
Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype. Eur J Haematol 2007; 79:508–515.
Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, et al. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86:793–800.
Morgani KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases [Review]. Annu Rev Med 2008:213–222.
Mossuz P, Bouamrani A, Brugiere S, Arlotto M, et al. Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera. Proteom Clin Appl 2007; 1:1605–1612.
Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials [Review]. Leukemia 2008; 22:23–30.
Rudzki Z, Sacha T, Stoj A, Czekalska S, et al. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more “erythremic” and less “thrombocythemic”: A molecular, histologic, and clinical study. Int J Hematol 2007; 86:130–136.
Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, et al. JAK2(V617F) mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93:34–40.
Schwernmers S, Will B, Waller CE, Abdulkarim K, et al. JAK2(V617F)-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007; 35:1695–1703.
Sotlar K, Bache A, Stellmacher F, Bultmann B, et al. Systemic mastocytosis associated with chronic idiopathic myelofibrosis - A distinct subtype of systemic mastocytosis-associated clonal hematological nonmast cell lineage disorder carrying the activating point mutations KITD816V and JAK2(V61'7F). J Molecular Diagnostics 2008; 10:58–66.
Williams DM, Kim AH, Rogers O, Spivak JL, et al. Phenotypic variations and new mutations in JAK2 V617F-neagative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007; 35:1641–1646.
Transplantation, transfusion and graft versus host disease
Abdelkefi A, Torjman L, Ladeb S, Sghaier Z, et al. Isolated extramedullary relapse in the breast of a patient with acute myeloid leukemia following allogeneic stem cell transplantation: Case report and review of the literature [Review]. Int J Hematol 2007; 85:149–153.
Acar GO, Acioglu E, Enver O, Ar C, et al. Unilateral sudden hearing loss as the first sign of chronic myeloid leukemia. Eur Arch Otorhinolaryngol 2007; 264:1513–1516.
Ayas M, Al-Jefri A, Al-Seraihi A, Al-Mahr M, et al. Allogeneic stem cell transplantation in Fanconi anemia patients presenting with myelodysplasia and/or clonal abnormality: update on the Saudi experience. Bone Marrow Transplant 2008; 41:261–265.
Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol 2008; 26:1180.
Breems DA, Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 2007; 44:259–266.
Chang MC, Chen TY, Tang JL, Lan YJ, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: No impact on early mortality and intracranial hemorrhage. Am J Hematol 2007; 82:976–980.
Chen MH, Chiou TJ, Lin PC, Gau JP, et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol 2007; 86:275–281.
Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008; 141:80–83.
Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML [Review]. Bone Marrow Transplant 2008; 41:415–423.
De Witte T, Suciu S, Brand R, Muus P, et al. Autologous stem cell transplantation in Myelodysplastic syndromes. Semin Hematol 2007; 44:274–277.
Faber E, Koza V, Vitek A, Mayer J, et al. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007; 54:443–446.
Flynn CM, Hirsch B, De For T, Barker JN, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. Am J Hematol 2007; 82:867–872.
Fontana V, Dudkiewicz P, Horstman L, Tzakis AG, et al. Atypical chronic myeloid leukemia following organ transplants. Clin Transplant 2008; 22:258–261.
Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060–1066.
Goldberg SL. Novel treatment options for transfusional iron overload in patients with mayelodysplastic syndromes. Leuk Res 2007; 31:S16–S22.
Gordon MK, Sher D, Karrison T, Kebriaei P, et al. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 2008; 49:531–537.
Gupta V. Alternative donor transplants for high-risk acute myeloid leukemia. Curr Opin Hematol 2008; 15:115–120.
Horny HP, Sotlar K, Valent P. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes [Review]. Leuk Res 2007; 31:1609–1616.
Huang Q, Wu YP, Snyder DS, Chang KL, et al. Clinical and Pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantation. Am J Clin Pathol 2007; 128:565–570.
Huisman C, Meijer E, Petersen EJ, Lokhorst HM, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant 2008; 14:181–186.
Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008; 112:1089–1095.
Kasner MT, Laury A, Kasner SE, Carroll M, et al. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol 2007; 82:1110–1112.
Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110:3456–3462.
Kim HJ, Choi Y, Min WS, Kim TG, et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 2007; 84:1082–1091.
Kohno A, Morishita Y, Iida H, Yanada M, et al. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2008; 87:210–216.
Korkaya H, Wicha MS. Selective targeting of cancer stem cells - A new concept in cancer therapeutics [Review]. Biodrugs 2007; 21:299–310.
Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis [Review]. Leukemia 2008; 22:474–486.
Loken MR, van de Loosdrecht A, Ogata K, Orfao A, et al. Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 2008; 32:5–17.
Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation [Review]. Biol Blood Marrow Transplant 2007; 13:1121–1134.
Lyubimova LS, Savchenko VG, Demidova IA, Zhelnova EI, et al. Transplantation of allogenic bone marrow in patients with chronic myeloid leukemia [Russian]. Gematol Transfuziol 2007; 52:27–31.
Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31:S2–S6.
Malcovati L, Cazzola M, Germing U. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application - Reply. J Clin Oncol 2008; 26:1181–1182.
Martino R, Valcarcel D, Brunet S, Sureda A, et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008; 41:33–38.
Massa FS, Rolon JM, Pavlovsky S. Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplantation. Hematology 2007; 12:487–488.
Muta T, Kato K, Eto T, Oku S, et al. Successful stem cell transplantation without Cryopreservation from a microchimeric haploidentical sibling for refractory acute myeloid leukemia complicated with critical thrombophlebitis and cellulitis. Int J Hematol 2007; 85:85–88.
Narimatsu H, Emi N, Kohno A, Iwai M, et al. High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 2007; 40:773–778.
Nestvold JM, Omdal BK, Dai KZ, Martens A, et al. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Transplantation 2008; 85:102–111.
Oliansky DM, Appelbaum F, Cassileth PA, Keating A, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: An evidence-based review [Review]. Biol Blood Marrow Transplant 2008; 14:137–180.
Porter J, Galanello R, Saglio G, Neufeld EJ, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80:168–176.
Pulini S, D'Amico E, Basilico R, Mereu M, et al. Portal venous thrombosis in a young patient with idiopathic myelofibrosis and intrahepatic extramedullary hematopoiesis: a difficult diagnosis, prognosis and management. Leukemia 2007; 21:2373–2375.
Quiroga V, Xicoy B, Ruiz-Xivillea N, Tapia G. Coexistence of hepatosplenic myeloid metaplasia of donor's cells and graft versus host liver disease in a recipient of an allogenic transplant of hematopoietic progenitors due to idiopathic myelofibrosis [Spanish]. Med Clin (Barc) 2008; 130:197.
Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML intergroup and CIBMTR. Biol Blood Marrow Transplant 2008; 14:187–196.
Schmid C, Labopin M, Nagler A, Bornhauser M, et al. Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007; 25:4938–4945.
Shenoy S, Smith FO. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin [Review]. Bone Marrow Transplant 2008; 41:141–148.
Siebolts U, Thiele J, Zander T, Ditschkowski M, et al. Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF. Oncol Rep 2008; 19:287–292.
Sierra J, Martino R, Sanchez B, Pinana JL, et al. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia [Review]. Bone Marrow Transplant 2008; 41:425–437.
Teofili L, Giona F, Martini M, Cenci T, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110:3384–3386.
Valcarel D, Martino R, Caballero D, Martin J, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577–584.
Wang Y, Wu DP, Sun AN, Jin ZM, et al. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol 2008; 87:167–171.
Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Med Hypotheses 2008; 70:128–136.
Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, et al. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Transplant Proc 2007; 39:2898–2901.
New developments in diagnosis, prognosis and risk factors
Al-Adnani M, Williams S, Anderson J, Ashworth M, et al. Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. Fetal Pediatr Pathol 2007; 26:193–197.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia 2008; 22:265–272.
Creutzig U, Buchner T, Sauerland MC, Zimmermann M, et al. Significance of age in acute myeloid leukemia patients younger than 30 years. Cancer 2008; 112:562–571.
Dore AI, Santana-Lemos BAA, Coser VM, Santos FLS, et al. The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol 2007; 82:1340–1343.
Estey EH. “Fairest of them all” for myelodysplastic syndromes. Blood 2008; 111:6.
Font P, Subira D. Expression of CD7 in myelodysplastic syndromes (MDS): Is this a truly prognostic factor? Leuk Res 2008; 32:185–186.
Fontana S, Alessandro R, Barranca M, Giordano M, et al. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines [Review]. J Proteome Res 2007; 6:4330–4342.
Garzon R, Garofalo M, Martelli MP, Briesewitz R, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105:3945–3950.
Graef T, Vaupel M, Fenk R, Ruf L, et al. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol 2007; 25:170–177.
Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007; 35:1708–1718.
Hussein K, Ketterling RP, Hulshizer RL, Kuffel DG, et al. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol 2008; 80:318–321.
Kantarjian H, O'Brien S, Shan J, Huang X, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia - Need for new response definitions? Cancer 2008; 112:837–845.
Kern W, Haferlach C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia [Review]. Cancer 2008; 112:4–16.
Lamba A, Dey P, Kumari S, Marwaha N. Prognostic significance of the histornorphometric features of bone marrow trephine biopsies in patients with chronic myeloid leukemia. Anal Quant Cytol Histol 2007; 29:370–376.
Landstrom AP, Knudson RA, Dewald GW, Ketterling RP, et al. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome. Leuk Lymphoma 2007; 48:2137–2140.
Lorand-Metze I, Califani SMV, Ribeiro E, Lima CSP, et al. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 2008; 32:211–213.
Lundan T, Juvonen V, Mueller MC, Mustjoki S, et al. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica 2008; 93:178–185.
Miettinen M, Kraszewska E, Sobin LH, Lasota J. A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer 2008; 112:645–649.
O'Malley DP, Orazi A, Dunphy CH, Coleman BR, et al. Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia. Mod Pathol 2007; 20:1166–1171.
Panteli K, Bai M, Hatzimichael E, Zagorianakou N, et al. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology 2007; 12:481–486.
Peterson L. Prefibrotic myelofibrosis: is this diagnosis valid? Blood 2008; 111:1–2.
Plesa C, Chelghoum Y, Plesa A, Elhamri M, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. Cancer 2008; 112:572–580.
Querclues G, Russo V, Martinez A, Sarra GM, et al. Retinal abnormalities in adult acute myeloid leukemia: semeiological features and prognostic correlations. Analysis of 178 cases [French]. J Fr Ophtalmol 2007; 30:819–823.
Roberson JR, Onciu M, Pounds S, Rubnitz JE, et al. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. Pediatric Blood Cancer 2008; 50:542–548.
Schiffer CA. World Health Organization and International Prognostic Scoring System: The limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Semin Hematol 2008; 45:3–7.
Solomon PR, Munirajan AK, Tsuchida N, Muthukumarasamy K, et al. Promoter hypermethylation analysis in myelodysplastic syndromes: Diagnostic & prognostic implication. Indian J Med Res 2008; 127:52–57.
Sorror ML, Sandmaier BM, Storer BE, Maris MB, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246–4254.
Stachurski D, Smith BR, Pozdnyakova O, Andersen M, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32:215–224.
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092–1097.
van de Loosdrecht AA, Westers TM, Ossenkoppele GJ. Flowcytometry in myelodysplastic syndromes: Towards a new paradigm in diagnosis and prognostication? Leuk Res 2008; 32:205–207.
Vener C, Fracchiolla NS, Gianelli U, Calori R, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111:1862–1865.
Wandt H, Schakel U, Kroschinsky F, Prange-Krex G, et al. MLF according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008; 111:1855–1861.
Wells DA, Ogata K. On flow cytometry in myelodysplastic syndromes, with caveats. Leuk Res 2008; 32:209–210.
Worch J, Ritter J, Fruhwald MC. Presentation of acute promyelocytic leukemia as granulocytic sarcoma. Pediatric Blood Cancer 2008; 50:657–660.
Zhang T, Grenier S, Nwachukwu B, Wei CH, et al. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring - Summary and recommendations. J Molecular Diagnostics 2007; 9:421–430.
Abecassis I, Maes J, Carrier JL, Hillion J, et al. Re-expression of DNA methylation-silenced CD44 gene in a resistant NB4 cell line: rescue of CD44-dependent cell death by cAMP. Leukemia 2008; 22:511–520.
Akoz AG, Dagdas S, Ozet G, Ceran F, et al. Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia. Hematology 2007; 12:419–422.
Alibhai SMH, Leach M, Kermalli H, Gupta V, et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults [Review]. Crit Rev Oncol/Hematol 2007; 64:19–30.
Almoznino-Sarafian D, Dotan E, Sandbank J, Gorelik O, et al. Unusual manifestations of myelofibrosis in a patient with congenital asplenia. Acta Haematol 2007; 118:226–230.
Altintas A, Karahan Z, Pasa S, Cil T, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 2007; 48:1981–1987.
Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008; 87:269–276.
Atallah E, Cortes J, O'Brien S, Pierce S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007; 110:3547–3551.
Belizna CC, Kerleau JM, Heron F, Cailleux N, et al. Vasculitis and myelodysplasia. Isr Med Assoc J 2008; 10:156–157, 2008 Feb.
Bergeron A, Rea D, Levy V, Picard C, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia - A case series. Am J Respir Crit Care Med 2007; 176:814–818.
Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, et al. Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice. Cytom Part A 2008; 73A:148–159, 2008 Feb.
Capra M, Vilella L, Pereira WV, Coser VM, et al. Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil. Leuk Lymphoma 2007; 48:2381–2386.
Cibull TL, Thomas AB, O'Malley DP, Billings SD. Myeloid leukemia cutis: a histologic and immunohistochemical review [Review]. J Cutan Pathol 2008; 35:180–185.
Della Porta MG, Malcovati L, Rigolin GM, Rosti V, et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008; 22:530–537.
Ermakova TA, Chelysheva EY, Turkina AG, Sokolova MA, et al. Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response [Russian]. Ter Arkh 2007; 79:13–16.
Ferrajoli A, Faderl S, Van Q, Koch P, et al. WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007; 67:11291–11299.
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008; 26:1532–1536.
Foss B, Bruserud O. Platelet functions and clinical effects in acute myelogenous leukemia [Review]. Thromb Haemost 2008; 99:27–37.
Fox E, Razzouk BI, Widemann BC, Xiao S, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma [Review]. Blood 2008; 111:566–573.
Galimberti S, Canestraro M, Pacini S, Fazzi R, et al. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 2008; 32:103–112.
Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007; 31:S10–S15.
Halim TY, Song KW, Barnett MJ, Forrest DL, et al. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 2007; 18:1246–1252.
Hudnall SD, Northup J, Panova N, Suleman K, et al. Prolonged preleukemic phase of chronic myelogenous leukemia. Exp Mol Pathol 2007; 83:484–489.
Huguet F, Giocanti N, Hennequin C, Croisy M, et al. Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. Mol Cancer Ther 2008; 7:398–406.
Inoue H, Matsushita K, Arima N, Hamada H, et al. High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. Leuk Lymphoma 2008; 49:315–321.
Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: An individualized approach to treatment. Cancer J 2007; 13:357–365.
Jiang GS, Albihn A, Tang TH, Tian ZG, et al. Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid. Leuk Res 2008; 32:297–307.
Kafetzakis A, Foundoulakis A, Ioannoua CV, Stavroulaki E, et al. Acute lower limb ischemia as the initial symptom of acute myeloid leukemia. In: Vasc Med 2007; 12:199–202.
Kaspers GJL, Zwaan CN. Pediatric acute myeloid leukemia: towards high-quality cure of all patients [Review]. Haematologica 2007; 92:1519–1532.
Kiladjian JJ, Visentin G, Vieyl E, Chevret S, et al. Activation of cytotoxic T-cell receptor gamma delta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008; 93:381–389.
Laredj LN, Ferguson BJ, Rich T. Microbial and acute phase stimuli disrupt promyelocytic leukemia tumor suppressive nodes. Mol Immunol 2008; 45:1477–1484.
Liang R, Huang GS, Wang Z, Chen XQ, et al. Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR. Int J Hematol 2008; 87:152–166.
Lichtman MA. Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis. Blood 2007; 110:3085–3086.
Lim DJ, Oh EJ, Park CW, Kwon HS, et al. Pancytopenia and secondary myelofibrosis could be induced by primary hyperparathyroidism. Int J Lab Hematol 2007; 29:464–468.
Martinez-Lavin M, Vargas A, Rivera-Vinas M. Hypertrophic osteoarthrapathy: a palindrome with a pathogenic connotation [Review]. Curr Opin Rheumatol 2008; 20:88–91.
Maule MM, Dama E, Mosso ML, Magnani C, et al. High incidence of acute promyelocytic leukemia in children in northwest Italy, 1980-2003: a report from the Childhood Cancer Registry of Piedmont. Leukemia 2008; 22:439–441.
Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1(low) mouse model of the disease. Exp Hematol 2008; 36:158–171.
Montesinos P, Lorenzo I, Martin G, Sanz J, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93:67–74.
Morimatsu Y, Matsubara S, Hirose N, Ohkuchi A, et al. Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption. Arch Gynecol Obstet 2008; 277:267–270.
Muto N, Tomokuni T, Haramoto M, Tatemoto H, et al. Isolation of apoptosis and differentiation-inducing substances toward human promyelocytic leukemia HL-60 cells from leaves of Juniperus taxifolia. Biosci Biotechnol Biochem 2008; 72.
Naina HV, Harris S. Unusual presentation of myelofibrosis. Internal Med J 2008; 38:70–NIL_5.
Naithani R, Tvagi S, Choudhry VP. Secondary myelofibrosis in children. J Pediatr Hematol Oncol 2008; 30:196–198.
Nakahara T, Lambert PF. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology 2007; 366:316–329.
Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options [Review]. Br J Haematol 2008; 140:610–624.
Pyrovolaki K, Mavroudi I, Papadantonakis N, Velegraki M, et al. Transforming growth factor-beta1 affects interleukin-10 production in the bone marrow of patients with chronic idiopathic neutropenia. Eur J Haematol 2007; 79:531–538.
Ritchie DS, McBean M, Westerman DA, Kovalenko S, et al. Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. Blood 2008; 111:2896–2898.
Ru YX, Zhao SX, Liu EB, Yang QY, et al. Ultrastructural characteristics of bone marrow in patients with hematological disease: A study of 13 cases. Ultrastruct Pathol 2007; 31:327–332.
Schaefer C, Krause M, Fuhrhop I, Schroeder M, et al. Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia 2008; 22:59–65.
Scheinemann K, Weitzman S, Hitzler J, Doyle J, et al. Isolated central nervous system relapse in childhood acute promyelocytic leukemia. J Pediatr Hematol Oncol 2008; 30:160–162.
Sessions J. Chronic myeloid leukemia in 2007. Am J Health-Syst Pharm 2007; 64:S4–S9.
Shih YY, Hsiao LT, Yang CF, Wu YC, et al. Dramatic remission of anemia after thymectomy in a patient of idiopathic myelofibrosis with thymoma. Int J Hematol 2008; 87:56–59.
Shimada A, Taki T, Tabuchi K, Taketani T, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: A study of the Japanese Childhood AML Cooperative Study Group. Pediatric Blood Cancer 2008; 50:264–269.
Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes to Cells 2008; 13:245–254.
Shioi Y, Tamura H, Yokose N, Satoh C, et al. Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res 2007; 31:1641–1648.
Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140:444–453.
Takeuchi J, Ly H, Yamaguchi H, Carroll KA, et al. Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells Mol Dis 2008; 40.
Valent P, Krieger O, Stauder R, Wimazal F, et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform [Review]. Eur J Clin Invest 2008; 38:143–149.
van Wageningen S, Breerns-de Ridder MC, Nigten J, Nikoloski G, et al. Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR alpha. Blood 2008; 111:1634–1643.
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable [Review]. Blood 2008; 111:2505–2515.
Weintraub M, Revel-Vilk S, Charit M, Aker M, et al. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma. J Pediatr Hematol Oncol 2007; 29:646–648.